Breast Cancer | Meet The Professor: Optimizing the Management of HER2-Positive Breast Cancer — Part 1

Featuring perspectives from Dr Mark Pegram, including the following topics:

• Introduction: Journal Club with Dr Pegram (0:00)
• Case: A woman in her mid 60s with ER/PR-negative, HER2-positive metastatic breast cancer after multiple lines of HER2-directed therapy with no evidence of disease after 8 years of pertuzumab/trastuzumab — Raman Sood, MD (22:35)
• Case: A woman in her early 60s with a 1.8-cm triple-positive invasive ductal carcinoma after partial mastectomy/axillary lymph node dissection (9 N+) receives adjuvant TCHP x 6 — Shaachi Gupta, MD, MPH (27:30)
• Case: A woman in her early 70s with de novo ER-positive, HER2-positive breast cancer develops asymptomatic, bilateral brain metastases on TCHP — Chris Prakash, MD (36:02)
• Case: A woman in her early 30s with ER/PR-positive, HER2-negative breast cancer after neoadjuvant dose-dense doxorubicin and cyclophosphamide -> paclitaxel and bilateral mastectomy, now with HER2-positive disease on repeat testing — Zanetta S Lamar, MD (46:08)
• Case: A woman in her mid 40s with triple-negative breast cancer at biopsy declines neoadjuvant therapy and at surgery has a 3.2-cm node-negative, HER2-positive tumor — Alan B Astrow, MD (53:20)

CME information and select publications